科伦博泰生物(06990.HK)抗PD-L1塔戈利单抗获上市批准

阿斯达克财经
21 Jan

科伦博泰生物-B(06990.HK) 公布,公司联合顺铂和吉西他滨用于一线治疗复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)的创新人源化单克隆抗体塔戈利单抗(科泰莱)已获中国国家药品监督管理局批准于中国上市。这是塔戈利单抗获批的第二项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-20 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10